Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 extension study of norucholic acid in primary sclerosing cholangitis
NL-OMON60318Phase 3Active, not recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of norursodeoxycholic acid in Primary Sclerosing Cholangitis (PSC), sponsored by Dr. Falk Pharma GmbH. Primary endpoints: Occurrence of treatment-emergent adverse events, Occurrence of serious treatment-emergent adverse events and 3 more. Started Sep 2025; status: active, not recruiting.
02
Drugs
norursodeoxycholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NL-OMON60318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60318.